The Zhitong Finance App learned that Yao Ming Biotech (02269.HK) published its 2026 interim report, with strong performance growth. Revenue increased 18.4% year on year to 11.8 billion yuan (up 23.4% year on year in US dollars), and adjusted net profit to mother increased 38.4% year on year to 3.3 billion yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.